Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 9/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299314 | 1.00 | FKBP1A (0.50) | FKBP1AHPGDTSHRP2RX7ALDH1A1 | |
| SCHEMBL27047902 | 0.86 | HPGD (0.52) | FKBP1AHPGDALDH1A1F2 | |
| SCHEMBL10761995 | 0.85 | FKBP1A (0.50) | FKBP1AHPGDTSHRALDH1A1F2 | |
| SCHEMBL28663248 | 0.83 | FKBP1A (0.53) | FKBP1AP2RX7 | |
| SCHEMBL21869824 | 0.83 | FKBP1A (0.53) | FKBP1AP2RX7 | |
| SCHEMBL6473564 | 0.83 | FKBP1A (0.50) | FKBP1AHPGDTSHRF2 | |
| SCHEMBL30882647 | 0.83 | FKBP1A (0.50) | FKBP1AHPGDTSHRF2 | |
| SCHEMBL21896757 | 0.83 | KMT2A (0.50) | FKBP1AHPGDTSHRP2RX7 | |
| SCHEMBL10759751 | 0.82 | USP2 (0.47) | FKBP1AHPGDALDH1A1 | |
| SCHEMBL21869799 | 0.82 | ITGB1 (0.52) | FKBP1AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | FKBP1A 1603/4885HPGD 3055/4885TSHR 4702/4885 |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | FKBP1A 1653/4885HPGD 2171/4885TSHR 1326/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | FKBP1A 1401/4885HPGD 2376/4885TSHR 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.